Immunotherapy master trial for advanced cancers
Part of Cancer clinical trials.
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 88 pounds (40 kg).
- You have advanced cancer that has spread or cannot be removed by surgery (including leukemia or lymphoma).
- You are willing to have blood drawn and a tumor biopsy (or bone marrow sample if needed).
- You agree to use effective birth control during the study if you or your partner could become pregnant.
- You are enrolled in French social security or health insurance.
- Your kidney, liver, and blood cell counts are within certain limits (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy before surgery for people with localized solid tumors. It aims to improve how well the cancer is controlled and may help shrink tumors so they can be removed more easily.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new immunotherapy drug (called MEDI5752) for people with certain solid tumors that have a special immune feature called 'mature tertiary lymphoid structures.' The drug is designed to help your immune system fight the cancer more effectively. You may be able to join even if you haven't had immunotherapy before, or if you had it and it stopped working after a while.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
This study is tracking how well a combination of two immunotherapy medicines (iparomlimab and tuvonralimab) works in people with advanced cancers. It's a real-world study, meaning you get the treatment as part of your regular care, and the researchers observe the results.
This trial tests a new immune cell therapy for people with advanced solid tumors (lung, liver, colorectal, or breast cancer). It aims to use your own immune cells to fight the cancer, and might help if standard treatments have stopped working.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.